4 news items
Travere Therapeutics Reports First Quarter 2024 Financial Results
TVTX
6 May 24
items, or cease to exclude items that it has historically excluded, for purposes of its non-GAAP financial measures; because of the non-standardized
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSLLY
TVTX
24 Apr 24
for purposes of regulatory review in the EU. Patients who completed the PROTECT double-blind portion of the study on treatment were eligible
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
CSLLY
TVTX
24 Apr 24
in eGFR chronic and total slope versus irbesartan achieving statistical significance in eGFR chronic slope for purposes of regulatory review in the EU
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
TVTX
11 Mar 24
achieving statistical significance in eGFR chronic slope for purposes of regulatory review in the EU. Patients who completed the PROTECT double-blind portion
- Prev
- 1
- Next